Numeral Ltd
Numeral Ltd is a healthcare diagnostics company that generates revenue primarily through the development and commercialization of diagnostic solutions for medical research and clinical applications.
Business. Numeral Ltd (NXII.MZ) is a healthcare diagnostics company operating within the biotechnology and medical research industry. The firm generates revenue through product sales and does not disclose specific operating segments or geographic breakdowns in the provided data. Headquarters location and primary exchange listing details are not specified in the available information.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Numeral Ltd (NXII.MZ) is a healthcare diagnostics company operating within the biotechnology and medical research industry. The firm generates revenue through product sales and does not disclose specific operating segments or geographic breakdowns in the provided data. Headquarters location and primary exchange listing details are not specified in the available information.
Numeral Ltd exhibits a highly leveraged capital structure, with total liabilities of $179,270 million and total equity of -$146,960 million, resulting in a negative debt-to-equity ratio of -0.71. The company's liquidity position is weak, as evidenced by a current ratio of 0.18 and only $300 million in cash and equivalents. The negative operating cash flow of -$16,420 million further exacerbates liquidity concerns.
Profitability metrics are mixed. The company reports a net income of $102,460 million and an operating income of $102,280 million, indicating strong top-line performance. However, the return on equity is negative at -69.72%, reflecting the impact of negative equity on returns. The return on assets of 3.17% is modest and below the industry median for biotechnology firms, which typically exceed 5%.
The company's revenue is concentrated in a single business segment focused on healthcare diagnostics, with no disclosed geographic diversification in the latest financial reports. This lack of diversification increases exposure to sector-specific risks and regulatory changes in the healthcare industry.
Growth trajectory is uncertain. While the company has reported a net income of $102,460 million, the negative operating cash flow and high debt levels suggest operational inefficiencies and financial strain. The outlook for the next fiscal year remains unclear without additional data on revenue growth or cost management initiatives.
Risk factors include liquidity constraints and a negative equity position, which could lead to financial distress or the need for additional capital. The risk assessment indicates a medium liquidity risk and a low dilution risk, with no immediate pressure for equity issuance. However, the negative net cash position after subtracting total debt is a key flag that warrants close monitoring.
Recent events include the latest financial filing, which discloses the company's negative equity and liquidity challenges. No recent earnings call transcripts or press releases have been analyzed to provide additional context on strategic initiatives or operational performance.
- Numeral Ltd has a negative equity position and a weak liquidity profile, with a current ratio of 0.18 and negative operating cash flow.
- Despite strong net and operating income, the company's return on equity is negative at -69.72%, indicating poor capital efficiency.
- Revenue is concentrated in a single diagnostics segment, with no geographic diversification disclosed.
- The company's growth trajectory is uncertain due to financial strain and lack of clear operational improvements.
- Liquidity risk is medium, and dilution risk is low, but the negative net cash position is a key concern.
Bull / Bear case
Generated · model-assistedNet income surged 123.7% year-over-year to $21,620, marking a significant turnaround from previous losses.
Operating income increased 120.3% to $21,430, demonstrating improved core operational profitability in the latest fiscal year.
The company's net margin of 1.23% ranks in the top quartile of its biotechnology cohort.
Operating margin of 1.23% places the firm above the 75th percentile among 258 biotechnology peers.
Dilution risk is assessed as low, suggesting limited immediate threat to existing shareholder equity value.
Cash conversion ratio of -0.16 ranks in the bottom quartile, indicating poor ability to generate cash from earnings.
Liquidity risk is rated as medium, potentially constraining the company's ability to meet short-term obligations.
In focus — financials by report
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Return On Assetsnet_income / total_assets
- Numeral Ltd Market data — financials · 2026-05-28
Ownership & reference
Leadership
- Dave van NiekerkChief Executive Officer, Executive Director